June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
ALTERATIONS IN VEGF, PEDF and PDGF LEVELS OF VITREOUS AND BLOOD IN RESPONSE TO INTRAVITREAL ANTI-VEGF THERAPY IN PATIENTS WITH DIABETIC MACULAR EDEMA
Author Affiliations & Notes
  • Umit Ubeyt Inan
    Ophthalmology, Kocatepe University, Afyon, Turkey
  • Onur POLAT
    Ophthalmology, Kocatepe University, Afyon, Turkey
  • Sibel INAN
    Ophthalmology, Kocatepe University, Afyon, Turkey
  • Tulay KOKEN
    Biochemistry, Kocatepe University Medical School, Afyon, Turkey
  • Mahmut KARADAS
    Ophthalmology, Kocatepe University, Afyon, Turkey
  • Mustafa DOGAN
    Ophthalmology, Kocatepe University, Afyon, Turkey
  • Kagan UCOK
    Physiology, Kocatepe University Medical School, Afyon, Turkey
  • Footnotes
    Commercial Relationships Umit Inan, None; Onur POLAT, None; Sibel INAN, None; Tulay KOKEN, None; Mahmut KARADAS, None; Mustafa DOGAN, None; Kagan UCOK, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 4717. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Umit Ubeyt Inan, Onur POLAT, Sibel INAN, Tulay KOKEN, Mahmut KARADAS, Mustafa DOGAN, Kagan UCOK; ALTERATIONS IN VEGF, PEDF and PDGF LEVELS OF VITREOUS AND BLOOD IN RESPONSE TO INTRAVITREAL ANTI-VEGF THERAPY IN PATIENTS WITH DIABETIC MACULAR EDEMA. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4717.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: The relationship of ocular angiogenesis related factors in vitreous and blood with macular edema and retinopathy severity and their changes before and after intravitreal ranibizumab injection in patients with diabetic patients were aimed to evaluate in our study.

Methods: Forty-two patients diagnosed with naïve diabetic macular edema undergoing anti-VEGF treatment included in this study. The patients underwent intravitreal ranibizumab injection as needed protocol (PRN) after the first 5 consecutive monthly injections. Vitreous samples were collected during the injection procedure when injection needle is in place at first and fourth injections. Blood samples were also collected at pre and after the first injection and at the day of fourth injection. The levels of vascular endothelial growth factor (VEGF), pigment epithelial derived factor (PEDF) and platelet derived growth factor (PDGF) were measured in both vitreous and blood samples. The levels of eritropoetin (EPO), angiopoetin-1 (ANG-1) and endostatin were also measured in blood samples.

Results: Thirty-three patients completed the study. Statistically significant improvement in BCVA (p<0.001) at month 3 (0.41±0.23) was obtained when compared to baseline BCVA (0.27±0.16). Baseline central subfield macular thickness was 474.48±103.67μm and improved to 344.39±109.91μm at month 3 (p<0.001). While baseline vitreous VEGF level (1560.67±2470.39pg/mL) significantly decreased to (748.27±498.07pg/mL), PDGF and PEDF levels did not change significantly (p:0.048, 0.254, 0.260, respectively). While serum levels of VEGF, ANG-1, EPO decreased significantly after the 1 day and 3 months after the first injection, PEDF levels showed significant elevation and the levels of PDGF and endostatin did not change significantly (p<0.001 and <0.001, p<0.001 and <0.001, p:0.013 and <0.001, p<0.001 and <0.001, p:0.189 and 0.067, p:0.056 and 0.17, respectively). Vitreous and serum levels of VEGF, PEDF and PDGF did not significant correlation before and after the intravitreal ranibizumab injections.

Conclusions: Intravitreal ranibizumab injection causes significant alterations in vitreous VEGF and serum VEGF, ANG-1, EPO, PEDF levels after 3 consecutive injections.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×